| 引用本文:牧辰1，潘中1，江南1，江孝华1，郝丽君1，秦碧勇2.复方斑蝥胶囊联合培美曲塞和铂类化疗对晚期肺腺癌患者疗效的影响[J].世界中医药,2023,(10):. |
|
| 复方斑蝥胶囊联合培美曲塞和铂类化疗对晚期肺腺癌患者疗效的影响 |
| Compound Cantharidin Capsules Combined with Pemetrexed+Cisplatin Chemotherapy Treats Patients with Advanced Lung Adenocarcinoma |
| 投稿时间：2022-12-13 |
| DOI：10.3969/j.issn.1673-7202.2023.10.013 |
| 中文关键词: 晚期肺腺癌 培美曲塞 一线化疗 复方斑蝥胶囊 近期疗效 无进展生存期 不良反应 安全性 |
| English Keywords:Advanced lung adenocarcinoma Pemetrexed First-line chemotherapy Compound cantharidin capsules Short-term therapeutic effect Progression-free survival Adverse reactions Safety |
| 基金项目:湖北省卫生健康委员会2019—2020年度指导性项目（WJ2019F049） |
|
| 摘要点击次数: 547 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探究复方斑蝥胶囊联合培美曲塞+铂类化疗对晚期肺腺癌患者疗效的影响。方法：选取2017年1月至2021年12月德驭医疗马鞍山总医院收治的晚期肺腺癌患者80例作为研究对象，随机分为观察组和对照组，每组40例。对照组接受培美曲塞+铂类药物一线治疗，观察组在对照组基础上加用复方斑蝥胶囊。比较2组近期疗效、肿瘤标志物水平、免疫功能、不良反应发生情况和无进展生存期（PFS）。结果：观察组客观有效率（ORR）、疾病控制率（DCR）均高于对照组（均P<0.05）。治疗后，观察组癌胚抗原（CEA）、组织多肽特异性抗原（TPS）、糖类抗原153（CA153）水平低于对照组，CD3+、CD4+、CD4+/CD8+水平高于对照组（均P<0.05）。观察组血小板下降、白细胞下降、胃肠道反应和骨髓抑制发生率低于对照组（均P<0.05）。观察组中位PFS长于对照组（P<0.05）。结论：复方斑蝥胶囊可提高培美曲塞+铂类药物治疗晚期肺腺癌的近期疗效，在降低肿瘤标志物水平的同时，改善患者免疫功能，减少不良反应发生。 |
| English Summary: |
| To observe the therapeutic effects of compound cantharidin capsules combined with pemetrexed+cisplatin chemotherapy on the patients with advanced lung adenocarcinoma.Methods:A total of 80 patients with advanced lung adenocarcinoma admitted to Deyu Medical Ma'anshan General Hospital from January 2017 to December 2021 were enrolled and randomized into an observation group(n=40) and a control group(n=40).The control group received pemetrexed+cisplatin as first-line chemotherapy，and the observation group was additionally administrated with compound cantharidin capsules.The short-term therapeutic effect，levels of tumor markers，immune functions，adverse reactions，and progression-free survival(PFS) were compared between the two groups.Results:The objective response rate(ORR) and disease control rate(DCR) in the observation group were higher than those in the control group(P<0.05).After treatment，the observation group showed lower levels of carcinoembryonic antigen(CEA)，tissue polypeptide-specific antigen(TPS)，and carbohydrate antigen 153(CA153) and higher CD3+，CD4+，and CD4+/CD8+ levels than the control group(P<0.05).In addition，the observation group had lower incidence of thrombocytopenia，leukopenia，gastrointestinal reactions，and myelosuppression and longer median PFS than the control group(P<0.05).Conclusion:Compound cantharidin capsules can improve short-term curative effect in the patients with advanced lung adenocarcinoma treated with pemetrexed+cisplatin，lower the levels of tumor markers，improve immune function，and reduce adverse reactions. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
